Why Integra LifeSciences Holdings (IART) Is Back In The Spotlight
Integra LifeSciences Holdings (IART) is back in the spotlight as senior executives prepare to address investors at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, in Boston.
Recent trading has been choppy for Integra LifeSciences Holdings, with the share price falling 7.3% over the past week and 15.0% over 30 days, yet still showing a 29.1% year to date share price return and a more muted 2.9% total shareholder return over the past year. This points to momentum that has cooled after earlier gains as investors reassess growth prospects and risk around upcoming milestones such as the Wells Fargo conference and the planned SurgiMend relaunch.
Scan how Integra LifeSciences Holdings compares to other potential healthcare opportunities by checking our curated list of 16 high quality undiscovered gems before the next catalyst hits the sector.
Integra LifeSciences Holdings has surged over the past six months yet slipped recently as doubts creep in. Are investors already paid for the turnaround, or does the current valuation still leave meaningful upside on the table?
Most Popular Narrative: 42.6% Undervalued
On the most followed narrative, Integra LifeSciences Holdings screens as materially cheaper than its $27.00 fair value, even after the recent pullback to $15.50.
The operating model transformation and culture of continuous improvement, combined with recent annualized cost savings initiatives, set up a virtuous cycle of operating leverage that could unlock ongoing EBITDA and net margin expansion well above Street expectations as macro and remediation headwinds normalize.
Want to see what sits underneath that margin story? The narrative leans heavily on steady revenue gains, a sharp profit swing, and a tighter future valuation multiple. The fair value rests on that mix of improving earnings quality and a more demanding but still grounded P/E assumption.
Result: Fair Value of $27.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Integra LifeSciences Holdings faces real pressure if remediation work drags or if further product recalls hit confidence and keep quality related costs elevated.
Find out about the key risks to this Integra LifeSciences Holdings narrative.
Next Steps
If the Integra LifeSciences Holdings story so far feels mixed, use that tension as a prompt to review the data yourself and move quickly while sentiment is still forming. To weigh both sides of the debate in one place, start with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Integra LifeSciences Holdings?
Do not stop with Integra LifeSciences Holdings. Fresh ideas often come from scanning outside your usual watchlist, and the right shortlist can save you weeks of guesswork.
- Target potential bargains that combine quality and valuation by reviewing the 31 high quality undervalued stocks tailored to investors hunting for mispriced opportunities.
- Prioritize resilience and sleep better at night by focusing on companies identified in the 11 resilient stocks with low risk scores that score well on stability metrics.
- Zero in on strong fundamentals and cleaner balance sheets by checking the list of solid balance sheet and fundamentals (23 results) before the next wave of capital rotates.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com